Fresh analysis reveals that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Research printed in a leading medical journal demonstrates that while overweight people frequently drop a large proportion of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing such drugs need to be aware of the potential of quick rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight in about one and a half years.
Comparing Therapies
The study, which examined dozens of studies involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
Scientists note that people who lose weight through diet and exercise typically experience a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Experts propose the way of the drugs explains the accelerated regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making binge eating far more likely."
A Chronic Disease?
Health authorities recommend the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the significant potential of relapse, the treatment is often life-long.
This view is reinforced by drug manufacturers, who say that the findings "highlight the persistent character of obesity," similar to managing diseases like hypertension.
Patient Experiences
Users who have discontinued the jabs explain a intense return of appetite.
"I experienced a switch activating and you become starving," said one woman.
This challenge is exacerbated if individuals have not adopted sustainable lifestyle or habit changes during treatment.
Widespread Interest
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and lasting health benefits likely depends on ongoing behavioural changes.
